Home › Trials › NCT00588185

Using PET scans to find spread of prostate cancer

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

Not applicable Interventional Memorial Sloan Kettering Cancer Center · NCT00588185

This study is testing if special PET scans can help find out how far prostate cancer has spread in patients whose cancer is getting worse.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment300 (estimated)
SexMale
SponsorMemorial Sloan Kettering Cancer Center Academic / other
Locations7 sites (Basking Ridge, New Jersey and 6 other locations)
Trial IDNCT00588185 on ClinicalTrials.gov

What this trial studies

This study utilizes PET imaging with two radiotracers, [18F]-Fluoro-2-Deoxy-D-Glucose and [18F] Dihydro-Testosterone, to identify areas of abnormal metabolism in patients with progressive prostate cancer. The research aims to evaluate the effectiveness of these imaging techniques in detecting tumor spread and assessing treatment outcomes. By comparing the uptake of these tracers in relation to conventional imaging studies, the study seeks to provide a more accurate assessment of disease progression. Additionally, it will explore the relationship between FDHT accumulation and androgen receptor expression in available tumor samples.

Who should consider this trial

Good fit: Ideal candidates include patients with histologically confirmed prostate cancer exhibiting progressive disease as indicated by imaging or rising PSA levels.

Not a fit: Patients with a history of severe allergic reactions to FDHT or FDG, or those with significant hepatic or renal impairment, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved detection and monitoring of prostate cancer progression, allowing for more tailored treatment strategies.

How similar studies have performed: Previous studies have shown promising results with similar imaging approaches, suggesting potential for success in this novel application.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients with histologically confirmed prostate cancer.
* Progressive disease manifest by either:
* Imaging modalities:
* Bone Imaging: New osseous lesions on bone imaging (bone scintigraphy or NaF PET scan) and/or MRI or CT: An increase in measurable soft tissue disease, or the appearance of new sites of disease. Or
* Biochemical progression: A minimum of three rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart.
* Visible lesions by either CT, bone imaging, or MRI consistent with disease.
* Informed consent.

Exclusion Criteria:

* Previous anaphylactic reaction to either FDHT or FDG
* Hepatic: Bilirubin \> 1.5 x upper limit of normal (ULN), AST/ALT \>2.5 x ULN, albumin \< 2 g/dl, and GGT \> 2.5 x ULN IF Alkaline phosphatase \> 2.5 x ULN
* Renal: Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min

Where this trial is running

Basking Ridge, New Jersey and 6 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Prostate CancerProgressive Prostate Cancer[18F]-Fluoro-2-Deoxy-D-Glucose[18F] Dihydro-TestosteronePet ImagingPet scan00-095
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.